Natco Pharma Strengthens Global Presence with 49% Stake in Adcock Ingram
Natco Pharma, a leading Indian pharmaceutical company, has strengthened its presence in the global market by increasing its stake in South African pharmaceutical company Adcock Ingram Holdings Proprietary Limited to 49%. This strategic move marks a significant milestone in Natco Pharma’s expansion plans.
Natco Pharma Acquires Additional Stake in Adcock Ingram
Natco Pharma Limited, headquartered in Hyderabad, has successfully completed the acquisition of an additional 13.25 per cent equity stake in Adcock Ingram, bringing its total shareholding to 49 per cent. The transaction was valued at approximately ZAR 1.81 billion, equivalent to around ₹1,060 crore at the prevailing exchange rate.
The acquisition was executed through Natco Pharma South Africa Proprietary Limited, the company’s wholly owned subsidiary in the country. This strategic move is expected to enhance Natco Pharma’s presence in the South African pharmaceutical market.
Second Leg of Natco’s Entry into Adcock Ingram
This acquisition marks the second leg of Natco’s entry into Adcock Ingram, following the company’s initial stake acquisition in 2025. The first acquisition involved a 35.75 per cent stake through participation in Adcock Ingram’s delisting process, which included a firm intention offer announced in July 2025, shareholder approval in October 2025, and transaction completion in November 2025.
Market Impact and Details
- Natco Pharma’s stock on the NSE was trading at ₹967.70 on Tuesday afternoon, down 1.25 per cent from the previous close of ₹979.95.
- The company carries a total market capitalisation of approximately ₹17,332 crore and is listed on the Nifty Smallcap 100 index.
- Adcock Ingram, established in 1891, is ranked second in South Africa’s private and public pharmaceutical market, holding a 10 per cent share of the private market and leading the over-the-counter pharmaceutical segment.
- The company is the largest supplier of hospital and critical care products in the country, with a portfolio that includes brands such as Panado, Allergex, and Myprodol.
Key Takeaways
- Natco Pharma has increased its stake in Adcock Ingram to 49 per cent, marking a significant milestone in the company’s expansion plans.
- The acquisition was valued at approximately ZAR 1.81 billion, equivalent to around ₹1,060 crore at the prevailing exchange rate.
- Natco Pharma’s stock on the NSE was trading at ₹967.70 on Tuesday afternoon, down 1.25 per cent from the previous close of ₹979.95.
FAQs
What is the significance of Natco Pharma’s acquisition of Adcock Ingram?
Natco Pharma’s acquisition of Adcock Ingram is a strategic move to strengthen its presence in the global pharmaceutical market. The acquisition is expected to enhance Natco Pharma’s presence in the South African pharmaceutical market.
What is the total market capitalisation of Natco Pharma?
Natco Pharma carries a total market capitalisation of approximately ₹17,332 crore.
What are the key brands in Adcock Ingram’s portfolio?
Adcock Ingram’s portfolio includes brands such as Panado, Allergex, and Myprodol.
Conclusion
Natco Pharma’s acquisition of an additional 13.25 per cent equity stake in Adcock Ingram marks a significant milestone in the company’s expansion plans. The acquisition is expected to enhance Natco Pharma’s presence in the South African pharmaceutical market. As a leading player in the global pharmaceutical market, Natco Pharma is poised for further growth and expansion in the coming years. Investors are advised to keep a close eye on the company’s performance and future developments.
